Loading
Gabelli Healthcare & WellnessRx Trust Stock: price and insider trades · United States
1 insider bought €465k of shares over the last 90 days, the latest filed 13 Oct 2026.
Gabelli Healthcare & WellnessRx Trust: what insiders have been doing
Gabelli Healthcare & WellnessRx Trust, classified in the Finance & Banking sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, 26 filings were filed, from 3 insiders.
On the market, 2 insiders bought (25 purchases totalling €21.9M) while 1 insider sold (1 sale totalling €16k). Netting one side against the other leaves €21.8M of net buying. Unlike grants, an open-market purchase is paid for by the insider, at the market price. The buyers include 1 major shareholder and 1 senior executive. One trade stands out by size: a purchase of €15.8M from Gabelli Mario J, disclosed on 5 November 2025.
The data flag 8 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The last insider purchase was made public on 13 October 2026, 5 days ago. Filings reach the SEC (Form 4) feed a median of 3 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Compared with its exchange (5,810 companies, median 19 filings), a count of 26 filings is above the norm. The full history, which starts in 2021, counts 83 purchases against 4 sales.
Other companies in the same sector with recent insider buying flagged by our signals: Redwood Trust Inc and First Guaranty Bancshares, Inc. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Insider Decl.
93
Thresholds
n/a
Buy Volume
€34M
83 ops. · all time
Sell Volume
€3M
4 ops. · all time
Who traded when
BuySaleSaba Capital Management, L.P.47 buys
Mario J. Gabelli16 buys
Anthonie C. Vanekris2 sales
Since the insiders bought
- -2.8%Entry US$9.89 · Close 12 Oct 2026 US$9.61
- -4.7%Entry US$9.65 · Close at T+90 US$9.20
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.63
Analyst consensus
Income statement
RevenueUS$3M
Net incomeUS$2.3M77.3% margin
Valuation
PER (trailing)16.9x
Balance sheet & cash
Market capUS$140.1M
Total debtUS$10.1k
Free Cash Flow-US$2.1M
Profitability & ownership
% insiders1.8%
% institutions41.0%
Last declaration on 13 October 2026
Declarations93 total
400 shares@ US$9.40Common StockSEC:0001510281-26-000340:0
Canonical exit: 6 Jan 2027 (T+90)
2,955 shares@ US$9.430.020% mcap0.6% of flowCommon StockSEC:0001510281-26-000335:0
Canonical exit: 5 Jan 2027 (T+90)
4,439 shares@ US$9.410.031% mcap0.9% of flowCommon StockSEC:0001510281-26-000331:0
Canonical exit: 4 Jan 2027 (T+90)
1,775 shares@ US$9.380.012% mcap0.4% of flowCommon StockSEC:0001510281-26-000327:0
Canonical exit: 3 Jan 2027 (T+90)
5,720 shares@ US$9.410.039% mcap1.2% of flowCommon StockSEC:0001510281-26-000322:0
Canonical exit: 30 Dec 2026 (T+90)
500 shares@ US$9.350.0034% mcap0.1% of flowCommon StockSEC:0001510281-26-000322:1
Canonical exit: 31 Dec 2026 (T+90)
519 shares@ US$9.520.0035% mcap0.1% of flowCommon StockSEC:0001510281-26-000318:0
Canonical exit: 29 Dec 2026 (T+90)
400 shares@ US$9.710.0027% mcap0.1% of flowCommon StockSEC:0001510281-26-000300:0
Canonical exit: 10 Dec 2026 (T+90)
500 shares@ US$10.080.0035% mcap0.1% of flowCommon StockSEC:0001510281-26-000290:0
Canonical exit: 2 Dec 2026 (T+90)
4,340 shares@ US$10.050.030% mcap1.0% of flowCommon StockSEC:0001510281-26-000282:0
Canonical exit: 25 Nov 2026 (T+90)
7,087 shares@ US$10.130.050% mcap1.6% of flowCommon StockSEC:0001510281-26-000275:0
Canonical exit: 19 Nov 2026 (T+90)
24,102 shares@ US$10.130.17% mcap5.4% of flowCommon StockSEC:0001510281-26-000273:0
Canonical exit: 17 Nov 2026 (T+90)
1,203 shares@ US$9.860.0083% mcap0.3% of flowCommon StockSEC:0001510281-26-000268:0
Canonical exit: 12 Nov 2026 (T+90)
200 shares@ US$9.930.0014% mcap0.0% of flowCommon StockSEC:0001510281-26-000266:0
Canonical exit: 9 Nov 2026 (T+90)
3,800 shares@ US$9.580.1% of flowCommon Shares, Par Value $0.001SEC:0001185533-26-000006:0
Canonical exit: 12 Apr 2026 (T+90)
990 shares@ US$9.580.0% of flowCommon Shares, Par Value $0.001SEC:0001185533-26-000004:0
Canonical exit: 8 Apr 2026 (T+90)
500,000 shares@ US$10.008.9% of flowSeries E Cumulative Preferred SharesSEC:0001185533-26-000001:0
Canonical exit: 26 Mar 2026 (T+90)
100,000 shares@ US$10.001.8% of flowSeries G Cumulative Preferred SharesSEC:0001185533-25-000016:0
Canonical exit: 26 Mar 2026 (T+90)
11,312 shares@ US$9.372.3% of flowCommon StockSEC:0001510281-25-000628:0
Canonical exit: 16 Mar 2026 (T+90)
2,500 shares@ US$9.68770.0% of flowCommon Shares, Par Value $0.001SEC:0001185533-25-000010:0
Canonical exit: 3 Mar 2026 (T+90)
2,000 shares@ US$9.119860.1% of flowCommon Shares, Par Value $0.001SEC:0001247238-25-000008:0
14,451 shares@ US$9.623.1% of flowCommon StockSEC:0001510281-25-000595:0
Canonical exit: 23 Feb 2026 (T+90)
1,800,000 shares@ US$10.179133.0% of flowSeries G Cumulative Preferred SharesSEC:0001185533-25-000007:0
Canonical exit: 28 Jan 2026 (T+90)
20,808 shares@ US$9.284.3% of flowCommon StockSEC:0001510281-25-000529:0
Canonical exit: 21 Jan 2026 (T+90)
6,122 shares@ US$9.291.3% of flowCommon StockSEC:0001510281-25-000523:0
Canonical exit: 19 Jan 2026 (T+90)
25 of 93 declarations
About Gabelli Healthcare & WellnessRx Trust
The Gabelli Healthcare & WellnessRx Trust (NYSE: GRX) is a U.S.-listed closed-end fund focused on the healthcare and wellness opportunity set. For international investors, GRX is not an operating healthcare company but an actively managed investment company run by Gabelli Funds, LLC, a subsidiary of GAMCO Investors. Its core mandate is long-term capital appreciation, with portfolio exposure typically tied to structural themes across healthcare services, pharmaceuticals, medical products, devices, and broader wellness-related businesses. ([gabelli.com](https://gabelli.com/wp-content/uploads/2026/01/closedEnd_FactSheets-4Q-2025_GRX.pdf))
The fund dates back to 2007, giving it a meaningful operating history through multiple market regimes, including periods of healthcare rotation, interest-rate volatility, and shifts in sentiment toward defensive growth assets. It is based in Rye, New York, United States, within the Gabelli management platform. Importantly for global investors, GRX trades on the NYSE, which provides exchange-listed liquidity and transparency under U.S. market rules. ([stockanalysis.com](https://stockanalysis.com/stocks/grx/company/?utm_source=openai))
Read moreShow less
GRX’s investment objective is straightforward: seek long-term growth of capital by investing in opportunities presented by the healthcare and wellness industries. That thematic focus gives the fund exposure to secular drivers such as population aging, innovation in therapeutics, rising healthcare spending, and demand for prevention-oriented and quality-of-life products and services. As a closed-end fund, its market price can diverge from net asset value, so investors must evaluate both underlying portfolio performance and the premium/discount dynamic of the listed vehicle. The 2024 annual report showed a slight decline in NAV for the year, while the publicly traded share price performed better, underscoring that distinction. ([gabelli.com](https://gabelli.com/wp-content/uploads/2025/04/GRXAnnualReport.pdf))
From a competitive standpoint, GRX sits in a specialized niche: a healthcare-focused closed-end fund with an established Gabelli brand and an active, security-selection-driven approach. Its appeal is not only sector exposure but also its distribution policy. The fund has paid quarterly distributions on its common shares since June 2012, and in February 2026 it declared a first-quarter cash distribution of $0.17 per share, up from the prior $0.15 level. That matters for income-oriented investors, especially in Europe, where yield consistency and distribution discipline are often central to portfolio construction. ([gabelli.com](https://gabelli.com/wp-content/uploads/2025/04/GRXAnnualReport.pdf))
Recent disclosures also reinforce that GRX remains an active, SEC-reporting listed vehicle rather than a static legacy trust. Its 2026 filings and fund communications indicate continued portfolio management under Gabelli Funds, alongside a reported total net asset base of roughly $233 million at the time of the February 2026 distribution announcement. In practical terms, GRX is best viewed as a niche NYSE-listed U.S. healthcare fund with a long-term growth mandate, a distribution-oriented profile, and sensitivity to both healthcare fundamentals and market pricing of closed-end funds. ([gabelli.com](https://gabelli.com/wp-content/uploads/2026/02/03-26-div_GRX-4.pdf))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
